Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patents

SARASOTA, Fla., May 27, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", ))), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced an expansion of its global intellectual property portfolio with the issuance of two patents, one each in Australia and New Zealand respectively.